231 related articles for article (PubMed ID: 20500493)
1. Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial.
Dantal J; Berthoux F; Moal MC; Rostaing L; Legendre C; Genin R; Toupance O; Moulin B; Merville P; Rerolle JP; Bayle F; Westeel PF; Glotz D; Kossari N; Lefrançois N; Charpentier B; Quéré S; Di Giambattista F; Cassuto E;
Transpl Int; 2010 Nov; 23(11):1084-93. PubMed ID: 20500493
[TBL] [Abstract][Full Text] [Related]
2. Incidence of delayed graft function and wound healing complications after deceased-donor kidney transplantation is not affected by de novo everolimus.
Albano L; Berthoux F; Moal MC; Rostaing L; Legendre C; Genin R; Toupance O; Moulin B; Merville P; Rerolle JP; Bayle F; Westeel PF; Glotz D; Kossari N; Lefrançois N; Charpentier B; Blanc AS; Di Giambattista F; Dantal J;
Transplantation; 2009 Jul; 88(1):69-76. PubMed ID: 19584683
[TBL] [Abstract][Full Text] [Related]
3. Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial.
Gullestad L; Iversen M; Mortensen SA; Eiskjaer H; Riise GC; Mared L; Bjørtuft O; Ekmehag B; Jansson K; Simonsen S; Gude E; Rundqvist B; Fagertun HE; Solbu D; Bergh CH
Transplantation; 2010 Apr; 89(7):864-72. PubMed ID: 20061999
[TBL] [Abstract][Full Text] [Related]
4. FTY720 and everolimus in de novo renal transplant patients at risk for delayed graft function: results of an exploratory one-yr multicenter study.
Tedesco-Silva H; Lorber MI; Foster CE; Sollinger HW; Mendez R; Carvalho DB; Shapiro R; Rajagopalan PR; Mayer H; Slade J; Kahan BD;
Clin Transplant; 2009; 23(5):589-99. PubMed ID: 19719728
[TBL] [Abstract][Full Text] [Related]
5. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial.
De Simone P; Metselaar HJ; Fischer L; Dumortier J; Boudjema K; Hardwigsen J; Rostaing L; De Carlis L; Saliba F; Nevens F
Liver Transpl; 2009 Oct; 15(10):1262-9. PubMed ID: 19790150
[TBL] [Abstract][Full Text] [Related]
6. Everolimus with very low-exposure cyclosporine a in de novo kidney transplantation: a multicenter, randomized, controlled trial.
Salvadori M; Scolari MP; Bertoni E; Citterio F; Rigotti P; Cossu M; Dal Canton A; Tisone G; Albertazzi A; Pisani F; Gubbiotti G; Piredda G; Busnach G; Sparacino V; Goepel V; Messa P; Berloco P; Montanaro D; Veroux P; Federico S; Bartezaghi M; Corbetta G; Ponticelli C
Transplantation; 2009 Nov; 88(10):1194-202. PubMed ID: 19935373
[TBL] [Abstract][Full Text] [Related]
7. 12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients.
Tedesco-Silva H; Vitko S; Pascual J; Eris J; Magee JC; Whelchel J; Civati G; Campbell S; Alves-Filho G; Bourbigot B; Garcia VD; Leone J; Esmeraldo R; Rigotti P; Cambi V; Haas T;
Transpl Int; 2007 Jan; 20(1):27-36. PubMed ID: 17181650
[TBL] [Abstract][Full Text] [Related]
8. Renal function three years after early conversion from a calcineurin inhibitor to everolimus: results from a randomized trial in kidney transplantation.
Mjörnstedt L; Schwartz Sørensen S; von Zur Mühlen B; Jespersen B; Hansen JM; Bistrup C; Andersson H; Gustafsson B; Solbu D; Holdaas H
Transpl Int; 2015 Jan; 28(1):42-51. PubMed ID: 25176389
[TBL] [Abstract][Full Text] [Related]
9. Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study.
Holdaas H; Rostaing L; Serón D; Cole E; Chapman J; Fellstrøm B; Strom EH; Jardine A; Midtvedt K; Machein U; Ulbricht B; Karpov A; O'Connell PJ;
Transplantation; 2011 Aug; 92(4):410-8. PubMed ID: 21697773
[TBL] [Abstract][Full Text] [Related]
10. Everolimus plus early tacrolimus minimization: a phase III, randomized, open-label, multicentre trial in renal transplantation.
Langer RM; Hené R; Vitko S; Christiaans M; Tedesco-Silva H; Ciechanowski K; Cassuto E; Rostaing L; Vilatoba M; Machein U; Ulbricht B; Junge G; Dong G; Pascual J
Transpl Int; 2012 May; 25(5):592-602. PubMed ID: 22471345
[TBL] [Abstract][Full Text] [Related]
11. Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation.
Cibrik D; Silva HT; Vathsala A; Lackova E; Cornu-Artis C; Walker RG; Wang Z; Zibari GB; Shihab F; Kim YS
Transplantation; 2013 Apr; 95(7):933-42. PubMed ID: 23422495
[TBL] [Abstract][Full Text] [Related]
12. De novo use of everolimus with elimination or minimization of cyclosporine in renal transplant recipients.
Novoa PA; Grinyó JM; Ramos FJ; Errasti P; Franco A; Aldana G; Pefaur J; Marti-Cuadros AM; Otero AB; Saval N; Oppenheimer F
Transplant Proc; 2011 Nov; 43(9):3331-9. PubMed ID: 22099791
[TBL] [Abstract][Full Text] [Related]
13. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF;
Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398
[TBL] [Abstract][Full Text] [Related]
14. Long-term results of kidney transplantation with cyclosporine- and everolimus-based immunosuppression.
Iaria G; Pisani F; Iorio B; Lucchesi C; De Luca L; Ielpo B; D'Andria D; Tariciotti L; Tisone G
Transplant Proc; 2006 May; 38(4):1018-9. PubMed ID: 16757249
[TBL] [Abstract][Full Text] [Related]
15. Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients.
Chan L; Hartmann E; Cibrik D; Cooper M; Shaw LM
Transplantation; 2010 Jul; 90(1):31-7. PubMed ID: 20517177
[TBL] [Abstract][Full Text] [Related]
16. De novo therapy with everolimus and reduced-exposure cyclosporine following pediatric kidney transplantation: a prospective, multicenter, 12-month study.
Grushkin C; Mahan JD; Mange KC; Hexham JM; Ettenger R
Pediatr Transplant; 2013 May; 17(3):237-43. PubMed ID: 23279564
[TBL] [Abstract][Full Text] [Related]
17. Multicenter trial of everolimus in pediatric renal transplant recipients: results at three year.
Ettenger R; Hoyer PF; Grimm P; Webb N; Loirat C; Mahan JD; Mentser M; Niaudet P; Offner G; Vandamme-Lombaerts R; Hexham JM;
Pediatr Transplant; 2008 Jun; 12(4):456-63. PubMed ID: 18466433
[TBL] [Abstract][Full Text] [Related]
18. Everolimus versus azathioprine in a cyclosporine and ketoconazole-based immunosuppressive therapy in kidney transplant: 3-year follow-up of an open-label, prospective, cohort, comparative clinical trial.
Gonzalez F; Espinoza M; Herrera P; Rocca X; Reynolds E; Lorca E; Roessler E; Hidalgo J; Espinoza O
Transplant Proc; 2010; 42(1):270-2. PubMed ID: 20172327
[TBL] [Abstract][Full Text] [Related]
19. Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction.
Castroagudín JF; Molina E; Romero R; Otero E; Tomé S; Varo E
Liver Transpl; 2009 Dec; 15(12):1792-7. PubMed ID: 19938140
[TBL] [Abstract][Full Text] [Related]
20. Conversion to everolimus in maintenance liver transplant patients: a multicenter, retrospective analysis.
Saliba F; Dharancy S; Lorho R; Conti F; Radenne S; Neau-Cransac M; Hurtova M; Hardwigsen J; Calmus Y; Dumortier J
Liver Transpl; 2011 Aug; 17(8):905-13. PubMed ID: 21384525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
